EHR market exceeded $20B in 2012

The EHR market exceeded $20 billion in 2012, according to Kalorama Information. The healthcare market research publisher says vendors should see robust sales this year and next as providers try to avoid U.S. government penalties for paper record use. Kalorama detailed the finding in its sixth annual report on the EHR market, EMR 2013: The Market for Electronic Medical Records.

Kalorama Information’s report said the EHR market reached $20.7 billion in 2012, a 15 percent increase from its 2011 $17.9 billion value. Kalorama includes revenues for EMR/EHR systems, CPOE systems and directly related services such as installation, training, servicing and consulting, which are key profit areas for companies, but does not include hardware or other IT systems unrelated to EMR such as billing systems.   

“Last year was particularly good for the EMR market,” said Bruce Carlson, publisher of Kalorama Information in a release. “Companies improved sales to physicians, while hospitals added upgraded systems to conform with Meaningful Use requirements.”

More than $12.3 billion in Meaningful Use incentive payments have been distributed to 219,000 eligible hospitals and healthcare professionals as of March 1. The incentives are driving physician adoption, according to the Kalorama report.    

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.